Hyderabad, 20 May: Suven Life Sciences Ltd (Venkat Jasti, Chairman and MD) announced on Tuesday that two of their new chemical entities (NCEs) were granted product patents in South Africa and China for the treatment of disorders associated with neuro-degenerative diseases. These patents are valid until 2024 and 2025 respectively.
Products out of these inventories, which are in pre-clinical development may be licensed out at the stage of clinical phase-I or phase-II stage.
Products out of these inventories, which are in pre-clinical development may be licensed out at the stage of clinical phase-I or phase-II stage.
Comments